Sequence: RQIKIWFQNRRMKWKKGGC
| Experiment Id | EXP001783 |
|---|---|
| Paper | Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-pene |
| Peptide | Penetratin (ANTP) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 10 mg/kg per dose (siRNA formulation); 2 doses spaced 2 days apart |
| Mixing Ratio | siRNA-spermidine N/P 8:1 during encapsulation |
| Formulation Format | Dual-ligand PLGA nanoparticles (folate + penetratin) via DSPE-PEG linkers; siRNA-loaded |
| Formulation Components | ANTP/FOL-NP loaded with luciferase siRNA; control groups include unmodified NP and ANTP/FOL-NP with scrambled/untargeted siRNA; chol-siRNA control |
| Size Nm | 150.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | NU/NU nude mice bearing subcutaneous luciferase-expressing KB xenograft tumors (female, 6 weeks old) |
| Administration Route | Intratumoral injection (2 doses, 2 days apart) |
| Output Type | In vivo luciferase gene silencing in tumor (7 days after initial treatment; tumor lysate luciferase assay) |
| Output Value | ~60% knockdown vs untreated; significant vs unmodified NP and ANTP/FOL-NP with control siRNA |
| Output Units | |
| Output Notes | Comparable to cholesterol-conjugated siRNA control. |
| Toxicity Notes | No detailed systemic toxicity reported for intratumoral dosing in this paper. |
| Curation Notes |